MEVACOR Drug Patent Profile

✉ Email this page to a colleague

When do Mevacor patents expire, and when can generic versions of Mevacor launch?

Mevacor is a drug marketed by Merck and is included in one NDA.

The generic ingredient in MEVACOR is lovastatin. There are thirty-three drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lovastatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mevacor

A generic version of MEVACOR was approved as lovastatin by ACTAVIS ELIZABETH on December 17^th, 2001.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for MEVACOR?
What are the global sales for MEVACOR?
What is Average Wholesale Price for MEVACOR?

Summary for MEVACOR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	127
Clinical Trials:	27
Patent Applications:	4,299
Drug Prices:	Drug price information for MEVACOR
DailyMed Link:	MEVACOR at DailyMed

Drug patent expirations by year for MEVACOR

Recent Clinical Trials for MEVACOR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Heart Health Research Center	Phase 4
AstraZeneca	Phase 4
Brigham and Women's Hospital	Phase 4

See all MEVACOR clinical trials

US Patents and Regulatory Information for MEVACOR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck	MEVACOR	lovastatin	TABLET;ORAL	019643-002	Mar 28, 1991		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Merck	MEVACOR	lovastatin	TABLET;ORAL	019643-003	Aug 31, 1987		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Merck	MEVACOR	lovastatin	TABLET;ORAL	019643-004	Dec 14, 1988		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for MEVACOR

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck	MEVACOR	lovastatin	TABLET;ORAL	019643-002	Mar 28, 1991	⤷ Sign Up	⤷ Sign Up
Merck	MEVACOR	lovastatin	TABLET;ORAL	019643-004	Dec 14, 1988	⤷ Sign Up	⤷ Sign Up
Merck	MEVACOR	lovastatin	TABLET;ORAL	019643-003	Aug 31, 1987	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for MEVACOR

See the table below for patents covering MEVACOR around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Zimbabwe	13480	HYPOCHOLESTEREMIC FERMENTATION PRODUCTS AND PROCESS OF PREPARATION	⤷ Sign Up
Israel	60219	HYPOCHOLESTEREMIC FERMENTATION PRODUCTS OF THE HMG-COA REDUCTASE INHIBITOR TYPE,THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM	⤷ Sign Up
Canada	1161380	PRODUITS DE FERMENTATION HYPOCHOLESTEROLEMIQUES ET PROCEDE DE PREPARATION (HYPOCHOLESTEREMIC FERMENTATION PRODUCTS AND PROCESS OF PREPARATION)	⤷ Sign Up
Spain	492384		⤷ Sign Up
Japan	S57163374	HYPOCHOLESTEROLEMIC FERMENTATION PRODUCT AND MANUFACTURE	⤷ Sign Up
Greece	69216		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for MEVACOR

Recent Clinical Trials for MEVACOR

Make Better Decisions: Try a trial or see plans & pricing